Adare, the global technology-driven oral dose CDMO, will mark CPHI with the announcement that it has partnered with Laxxon Medical to provide GMP 3D oral dose printing from Adare’s Pessano facility in Milan.

Serán BioScience, the development-stage CDMO based in Bend, Oregon, has secured a $200 mn investment from Bain Capital to support the building of its first large-scale commercial manufacturing facility. The new site will enhance Serán’s capabilities in drug development and production to support a growing pipeline of pharmaceutical innovations.

The U.S. company’s initial public offering (IPO) on the Nasdaq index raised $362 mn, which the company says it will use to support pivotal Phase 2/3 trials for its lead asset - ficerafusp alfa - targeting head and neck squamous cell carcinoma. The listing follows a broader uptick in biotech IPO activity, with Zenas BioPharma and MBX Biosciences also going public, marking one of the busiest biotech IPO weeks in 2024. 

Global electronics company Molex, through its subsidiary Phillips Medisize, has entered into an agreement to acquire Vectura Group Limited from Philip Morris International. Vectura, based in the UK, specializes in inhalation drug delivery, including device and formulation development for dry powder inhalers, metered dose inhalers, and nebulizer products.

Agilent Technologies has completed its acquisition of BIOVECTRA, a Canadian CDMO specializing in biologics, highly potent pharmaceuticals, and targeted therapeutics. Now part of Agilent's Diagnostics and Genomics Group, the acquisition will enhance Agilent's portfolio with advanced manufacturing capabilities for gene editing and biologics production.

Sanner Group, the healthcare packaging and medical device CDMO, has announced it has acquired Gilero, a medical device designer, developer, and contract manufacturer headquartered in Durham, North Carolina. The acquisition helps position Sanner as a leading provider of end-to-end services across drug delivery, diagnostics, and MedTech device sectors. Gilero brings with it 130 engineers based across facilities in the U.S., Mexico, and Ireland.

Biotech firm eGenesis has raised $191 mn to advance its genetically modified pig kidney transplant program, utilizing its gene-editing technology that makes pig organs more compatible with human immune systems. The raised funds will be used to support clinical trials for the company's lead candidate - EGEN-2784 - a pig kidney engineered to be human-compatible after successful, though short-lived, human transplant earlier in 2024.

Eli Lilly has entered a major collaboration with Swiss biotech Haya Therapeutics to develop innovative drugs targeting metabolic conditions like obesity. The partnership, which could be as valuable as $1 bn, focuses on exploring the "dark genome" — the 98% of human DNA that does not code for proteins but plays critical regulatory roles.

In a deal worth up to $409 mn, Eli Lilly has partnered with Genetic Leap to accelerate RNA-targeted drug discovery using AI. The collaboration will focus on developing oligonucleotide therapies for key diseases; enhancing Lilly’s growing expertise in RNA-based treatments.

Superluminal Medicines has closed a $120 mn Series-A funding round to accelerate its drug discovery efforts focused on G protein-coupled receptor (GPCR) targets, a key class of membrane proteins involved in many diseases. The company employs a combination of generative biology, chemistry, and machine learning to rapidly develop candidate-ready compounds, focusing on membrane receptors that are often challenging to target.

CoreRx, Societal CDMO, and Bend Bioscience have announced a merger under the Bend Bioscience brand to create, they say, a unified, world-class CDMO combining the expertise and capabilities of the three companies to enhance their service offerings in pharmaceutical development and manufacturing.

Global API CDMO, ST Pharm, and mRNA bioprocessing provider, Quantoom Biosciences, have announced a supply agreement for an extended collaboration on Quantoom's proprietary SmartCap technology.

Bora Pharmaceuticals has successfully completed the acquisition of a sterile fill-finish manufacturing facility in Baltimore-Camden, Maryland, from Emergent BioSolutions. The acquisition allows Bora to expand its manufacturing capabilities in the U.S., particularly in the production of sterile injectables, and complements its existing drug substance capabilities.

NEC Bio Therapeutics and AGC Biologics have partnered to advance the production of NECVAX-NEO1, a personalized, orally delivered cancer vaccine targeting patient-specific tumor neoantigens. The partnership aims to enhance the development and delivery of personalized cancer treatments using AI and traditional biologics and will leverage AGC Biologic’s expertise in microbial fermentation.

Thermo Fisher Scientific has announced plans to acquire Sweden-based Olink Holding AB for approximately $3.1 bn in order to leverage Olink’s validated protein biomarker targets and advanced proteomics solutions, including its Proximity Extension Assay (PEA) technology. The transaction is expected to close by mid-2024, subject to regulatory approvals and customary conditions.

MedPharm and Tergus Pharma have announced a merger to create a leading CDMO specializing in topical and transepithelial pharmaceuticals, and will continue to operate using the MedPharm name.

The merger allows the new company to offer comprehensive drug development and manufacturing services.

Aptamer Group and AstraZeneca have announced a strategic collaboration following promising initial results with Aptamer's fibrotic liver delivery vehicles.

The partnership will focus on addressing the challenges of precise siRNA delivery, with the hope of revolutionizing therapeutic applications with Aptamer’s Optimer® technology.

Samsung Biologics voluntarily disclosed that it has secured a six-year deal with an unnamed U.S.-based pharmaceutical company, having secured a letter of intent signed in June. The contract runs through to the end of 2030.

AstraZeneca says the acquisition will enhance its oncology portfolio with Fusion’s expertise in radioconjugates (RCs), a type of drug that combines radiation with a tumor-targeting agent.

South Korea's Lotte Biologics and Germany's Merck KGaA have signed a partnership to enhance biopharmaceutical production and process development as part of Lotte's "Bio Venture Initiative" at their Songdo Bio campus in South Korea.